Auvelity ema approval 2025?

Short answer: I don’t have live access to EMA’s current status. As of my last update (mid-2024), Auvelity had not been approved by the European Medicines Agency (EMA). I can’t confirm whether it’s approved in 2025 without checking the latest sources.

If you want to verify the current status, here are the best places to check:
- EMA website: search for Auvelity or the active ingredient names (dextromethorphan/quinidine) in the European Medicines Portal.
- EMA press releases and the EMA “Public Assessment Reports” for any marketing authorization decisions.
- The drug’s sponsor/company investor relations pages for EU submission updates and timelines.

Regulatory timelines (general context):
- In the EU, after a marketing authorization application is validated, the EMA typically has around 12-15 months (sometimes longer) to issue a CHMP opinion and the European Commission then issues the final decision.
- Real-world outcomes depend on the data package, safety profile, and any (if-then) additional data requests.

If you’d like, I can help summarize the latest public statements you provide or guide you through locating the current EMA status.